Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Cash & Equivalents · Q2 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 2.5% from a year ago
Cash & equivalents stood at $7.75M at the end of Q2 FY2026, up 2.5% from a year earlier and down 10.7% from the prior quarter. Over 3 fiscal years it compounded at -22.5% a year.
Context
- Cash & equivalents amounted to 35.4% of total assets at the end of Q2 FY2026, down 4.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +2.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 8.08M USD
- Year-over-year change
- -45.9%
- 4-year CAGR
- -13.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 8.08M | -45.9% |
| FY2024 | 2024-09-30 | 14.93M | -36.2% |
| FY2023 | 2023-09-30 | 23.39M | +34.5% |
| FY2022 | 2022-09-30 | 17.4M | +20.2% |
| FY2021 | 2021-09-30 | 14.48M | — |
Cash & Equivalents vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's Mar 2026 cash & equivalents of $7.75M is the 7th highest of the 9 companies compared; the peer median is $36.52M.
- Its year-over-year change of +2.5% is the 7th highest of 9, against a peer median of +23.4%.
- Cash & equivalents amounts to 35.4% of total assets for OTLK, versus a peer median of 73.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | Mar 2026 | $917.55M | +30783.5% | +1063.1% | 12570.5% |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Mar 2026 | $51.05M | -1.6% | -9.8% | 15.6% | |
| Jun 2026 | $21.99M | -71.7% | -23.5% | 91.0% | |
| Mar 2026 | $16.38M | +24.7% | -19.3% | 53.0% | |
| Mar 2026 | $7.75M | +2.5% | -22.5% | 35.4% | |
| Mar 2026 | $6.71M | +21.0% | -27.0% | 56.4% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding OTLK) | $36.52M | +23.4% | -14.5% | 73.7% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.48M | 17.4M | 23.39M | 14.93M | 8.08M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 1.49M |
| Inventory | 0 | 0 | 0 | 0 | 3.34M |
| Other Current Assets | 324 | 0 | 7.59M | 12.49M | 4.48M |
| Total Current Assets | 21.51M | 27.52M | 30.98M | 27.42M | 17.39M |
| Property, Plant & Equipment (Net) | 275.05K | 70.36K | 26.17K | 274.65K | 225.51K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 853.66K | 804.93K | 793.93K | 693.19K | 552.18K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 174.59K | 132.02K | 501.3K | 439.28K | 417.52K |
| Total Non-current Assets | 1.3M | 1.01M | 1.32M | 1.41M | 1.2M |
| Total Assets | 22.81M | 28.53M | 32.3M | 28.82M | 18.58M |
| Account Payables | 2.2M | 3.49M | 6.57M | 7.97M | 10.19M |
| Short-term Debt | 904.2K | 10.92M | 35.55M | 29.44M | 29.95M |
| Tax Payables | 1.86M | 1.86M | 1.86M | 1.86M | 302B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | (217) | 1.45M | 1.83M | 1.01M | 3.03M |
| Total Current Liabilities | 6.75M | 19.73M | 46.73M | 42.55M | 45.81M |
| Long-term Debt | 10.89M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 522.92K | 57.14K | 6.22K | 59.1M | 4.77M |
| Total Non-current Liabilities | 11.45M | 61.41K | 6.22K | 59.35M | 4.96M |
| Total Liabilities | 18.2M | 19.79M | 46.74M | 101.9M | 50.77M |
| Common Stock | 1.76M | 2.27M | 2.6M | 239.06K | 538.87K |
| Retained Earnings | (342.88M) | (408.94M) | (467.92M) | (543.28M) | (605.71M) |
| Accumulated OCI | (22.81T) | 417.67M | (32.3T) | 0 | 0 |
| Other Stockholders Equity | (167) | (28.53T) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 4.61M | 8.74M | (14.44M) | (73.08M) | (32.19M) |
| Total Debt | 11.9M | 10.96M | 35.56M | 29.74M | 30.19M |
| Net Debt | (2.57M) | (6.44M) | 12.16M | 14.81M | 22.11M |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.